The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

The FDA approval of ruxolitinib for intermediate and high-risk myelofibrosis in 2011 changed the therapeutic landscape of the disease. We investigated the first-line treatment choices for MF patients in the pre- and post-ruxolitinib eras and found that the increased use of ruxolitinib has come at the expense of several agents, but has not significantly affected the utilization of hydroxyurea in the first-line setting.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 4, 2017 Category: Hematology Authors: Andrew T. Kuykendall, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji Source Type: research